• Cellav Health and Aesthetics, a Pluri subsidiary, completed development and U.S. cosmetic product listings for Regenativo+ and Placento+.
• U.S. commercial launch targeted for 2026, positioning Cellav to enter the professional regenerative aesthetics channel.
• Cellav opened talks with U.S. distributors and clinic networks, seeking initial commercial orders and broader adoption by licensed providers.
• Pluri cited clinical data supporting ingredient performance, including statistically significant improvements across multiple skin-quality measures with no meaningful adverse events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pluri Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020730PRIMZONEFULLFEED9730392) on June 02, 2026, and is solely responsible for the information contained therein.